Asuragen is celebrating encouraging clinical data, suggesting one of its molecular diagnostic tests is better than existing standards of care in determining how likely a woman will have a child with Fragile X syndrome--a genetic cause of autism spectrum disorders and other intellectual disabilities.
Primarily known for its work on Fragile X, a well-known autism target, Afraxis says that the giant Roche subsidiary will pay up to $187.5 million in milestones and an undisclosed upfront in order to develop the compounds for a "novel target."
Roche has tapped assets from biotech startup Seaside Therapeutics to advance pioneering treatments for Fragile X syndrome and autism spectrum disorders.
Scientists at F. Hoffman-La Roche in Switzerland and the Picower Institute for Learning at the Massachusetts Institute of Technology believe they've found a new compound that reverses most Fragile X-related symptoms in adult mice.
A European research effort led by Roche ( $RHHBY ) and others to tackle autism spectrum disorders nailed down $38.7 million in financing for what will be a massive, 5-year project seeking to come up with new diagnostic and treatment options.
San Diego-based Afraxis is getting some key support from the National Institutes of Health as it journeys through the dreaded "valley of death" with an experimental program for Fragile X syndrome--a
Swiss drugmaker Roche has begun a Phase II study of a candidate to treat Fragile X syndrome, a condition that is the most common cause of autism yet identified, the FRAXA Research Foundation
Experimental drugs aimed at correcting three rare conditions linked with autism are beginning early-stage human trials. These therapies are targeted at Rett syndrome, fragile X , and tuberous